You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
24 December 2021
Sweden’s Karo Pharma is set to acquire the E45 dermatology brand from Reckitt in a deal worth GBP200 million (USD268 million).
17 December 2021
Reckitt and Recordati have announced people appointments.
2 November 2021
Reckitt has extended its Mucinex cough and cold brand in the US with a line of products to “help sore throat sufferers power through without the pain”.
2 November 2021
Medlab Clinical has sold its Australian nutraceuticals business to PharmaCare and Reckitt has sold its stake in Mead Johnson Nutrition Argentina.
19 August 2021
Reckitt’s Nuromol has become the first combination medicine containing ibuprofen and paracetamol to be allowed on general sale outside pharmacies in the UK. The company has been awarded one year of data exclusivity for studies carried out to support the switch from pharmacy (P) to general-sale list...
28 July 2021
Worldwide sales of Reckitt’s OTC brands fell by more than 30% in the first half of 2021, but the company said trends had “improved as the second quarter progressed” and “retailer stocks are now at more normal levels”.
28 July 2021
Worldwide sales of Reckitt’s vitamins, minerals and supplements (VMS) portfolio fell by 15% in the first half of 2021 as Neuriva recorded “exceptionally strong growth” but Airborne struggled in the “weak cold and flu season”.
21 June 2021
Reckitt has announced that Aditya Sehgal – a member of its executive team – is leaving the company after 27 years.
8 June 2021
Reckitt is divesting its Infant Formula and Child Nutrition (IFCN) business in China to private-equity firm Primavera Capital Group in a transaction valuing the business at USD2.2 billion.
17 May 2021
Reckitt is seeking to switch its Nuromol combination pain reliever from pharmacy (P) to general-sale list (GSL) status in the UK.